Comparative Safety, Immunogenicity, and Efficacy of CEF Cell-Based and DF-1 Cell Line Adapted Infectious Bursal Disease Vaccines in Specific-Pathogen-Free Chickens.

Infectious bursal disease (IBD) is an immunosuppressive and economically important disease of young chickens caused by infectious bursal disease virus (IBDV). The National Veterinary Institute (Bishoftu, Ethiopia) produces intermediate IBDV vaccine using primary chicken embryo fibroblast (CEF) cells, a method with technical and economical cumbersome. This study assessed the safety, immunogenicity, and efficacy of DF-1 cell line-adapted IBDV LC-75 vaccine strain in reference to the CEF-based vaccine. Confluent monolayer of DF-1 cells was infected with IBDV and cells with cytopathic effects were passaged until 3rd passage. Viral growth was confirmed using a one-step RT-PCR targeting IBDV VP2 gene. Viral titer increased from 1st passage through 3rd passage. Safety was assessed in 30 specific-pathogen-free chickens (15 chickens/group) injected with 10-fold field dose of each vaccine intraocularly and monitored for 21 days. For immunogenicity and efficacy, 60 specific-pathogen-free chickens were grouped into 3 (20 chickens/group). First and 2nd group received DF-1 cell and CEF-based IBDV vaccines, respectively. The 3rd group served as unvaccinated control. Antibody response was measured using iELISA. Chickens were challenged 4 weeks postvaccination with very virulent IBDV (vvIBDV) intraocularly and followed-up for 10 days. Vaccination did not cause any adverse reactions during the 21 days of follow-up. In addition, both vaccines induced higher antibody titer 14 and 24 days-post-vaccination as compared to unvaccinated controls (p < 0.05). Moreover, DF-1 and CEF-based IBDV LC-75 vaccines rendered a complete protection against vvIBDV. Contrarily, morbidity and mortality in unvaccinated chickens was 50% and 30%, respectively. The results indicated that DF-1 and CEF cell-based IBDV vaccines are comparably immunogenic and efficacious. Therefore, DF-1 cell-line can be considered an affordable and convenient alternative to the CEF-based approach. The suitability of DF-1 cells to grow other IBDV strains and safety of these vaccines on bursa of Fabricius should further be investigated.

Immunogenicity and Efficacy Evaluation of Vero Cell-Adapted Infectious Bursal Disease Virus LC-75 Vaccine Strain.

INTRODUCTION: Infectious bursal disease virus (IBDV) is an avian viral pathogen that causes infectious bursal disease (IBD) of chickens. The disease has been endemic in Ethiopia since 2002, and vaccination has been practiced as the major means of disease prevention and control. An IBD vaccine is produced in Ethiopia using primary chicken embryo fibroblast (CEF) cell, which is time-consuming, laborious, and uneconomical. The present study was carried out to develop cell-based IBDV LC-75 vaccine using Vero cells and to evaluate the safety, immunogenicity and protection level. METHODS: Identity of the vaccine seed was confirmed with gene-specific primers using reverse transcription polymerase chain reaction (RT-PCR). Confluent monolayer of Vero cells was infected with vaccine virus and serial passage continued till passage 10. A characteristic virus-induced cytopathic effect (CPE) was observed starting from passage 2 on the third day post-infection. The infectious titer of adapted virus showed a linear increment along the passage level. The virus-induced specific antibody was determined using indirect ELISA after vaccination of chicks through ocular route. RESULTS: The antibody titer measured from Vero cells vaccinated chicks revealed similar level with the currently available CEF cell-based vaccine, hence no significant difference. Chicks vaccinated with Vero cell adapted virus showed complete protection against very virulent IBDV, while unvaccinated group had 60% morbidity and 25% mortality. CONCLUSION: It is concluded that the IBDV vaccine strain well adapted on Vero cells and found to be immunogenic induces antibody development and successfully protects chicks against challenge with the circulating field IBDV isolate. Hence, it is recommended to produce IBD vaccine using Vero cell culture at the industrial scale to conquer the limitations caused by using CEF cells and thus to vaccinate chicks population to protect against the circulating IBDV infection.

Sequence-based comparison of field and vaccine strains of infectious bursal disease virus in Ethiopia reveals an amino acid mismatch in the immunodominant VP2 protein.

Sequencing of the VP2 region was carried out to identify amino acid mismatches between vaccine strains and field isolates of infectious bursal disease virus (IBDV). Viruses were isolated in chicken embryo fibroblast (DF-1) cells using pooled samples of bursa collected from nine outbreaks, which affected 30,250 chickens in five localities, with an overall mortality of 47.87%. Virus strains were identified by comparing the deduced amino acid sequence between positions 232 and 446 of the immunodominant VP2 epitope. All of the pooled samples were positive for IBDV. RT-PCR yielded a 645-bp DNA fragment of the VP2 gene. Phylogenetic analysis of this fragment revealed clustering of these isolates with very virulent IBDV strains. The amino acid sequences of these isolates were identical to those of the European very virulent strains UK 661 and DV 86, except at position 222, but differed from the vaccine strains used in Ethiopia, suggesting the possible introduction of virulent virus strains to Ethiopia from Europe. Our study demonstrates the widespread presence of very virulent strains of IBDV on poultry farms in Ethiopia and demonstrates the need to evaluate the protective level of existing vaccines against circulating field viruses.

Prevalence of Pulmonary Tuberculosis and Associated Factors Among HIV Positive Patients Attending Antiretroviral Therapy Clinic at Arba Minch General Hospital, Southern Ethiopia.

BACKGROUND: Tuberculosis (TB) is an extremely contagious disease detrimentally affecting virtually every organ, most importantly the lungs. Pulmonary complications have been one of the commonest causes of morbidity and mortality since the advent of AIDS (Acquired Immune Deficiency Syndrome) pandemic. The AIDS virus has considerably reshape the epidemiology of TB by widening the risk of reactivating latent TB, increasing the possibility of TB infection once contracted to tubercle bacilli (re-infection) and by elevating the risk of rapid progression instantly after the infection. In this background, this study is intended to understand the prevalence of pulmonary tuberculosis and associated factors amongst Human Immunodeficiency Virus (HIV) positive patients attending antiretroviral therapy (ART) clinic in Arba Minch General hospital during the study period (March to May, 2016). METHODS: A cross-sectional study was carried out at Arba Minch Hospital from March to May, 2016. To assess the associated factors, a pre-tested structured questionnaire has been used. Sputum samples were collected and examined microscopically by using acid fast staining. The data was analyzed using Statistical Package for Social Services, version 20. RESULTS: Totally, 291 HIV positive patients were included in this study of which 71.5% were females and 28.5% were males. It was found that 42.3% of respondents were in the age ranged between 31-40 years. Of the 291 patients screened, 21 were positively diagnosed with pulmonary TB making the overall prevalence rate of 7.2%. From this study, it was revealed that CD4 count, previous history of tuberculosis and smoking were the significant predictors of tuberculosis (p˂0.05) in HIV patients. CONCLUSION: The results of the present study envisaged that the prevalence of HIV/TB co-infection was 7.2%. Previous history of TB, CD4 count less than 200/µl, and smoking habit were the possible risk factors elucidated. Therefore, TB screening among HIV-positive patients, public awareness, and community mobilization should be encouraged.